In certain aspects, the present disclosure provides methods and materials for the treatment of cancer. In accordance with some forms, the disclosure provides methods for the treatment of cancer which include inhibition of ubiquitin carboxyl-terminal hydrolase.

In certain aspects, the present disclosure provides methods and materials for the treatment of cancer. In accordance with some forms, the disclosure provides methods for the treatment of cancer which include inhibition of ubiquitin carboxyl-terminal hydrolase.

Methods and kits are disclosed for measuring activity of a methyltransferase or a radical SAM enzyme or for screening for an inhibitor of a methyltransferase or a radical SAM enzyme, where the methods and kits comprise, respectively, deaminase TM0936 for a MTase coupled assay and deaminase PA3170 for a radical SAM coupled assay.

Methods and kits are disclosed for measuring activity of a methyltransferase or a radical SAM enzyme or for screening for an inhibitor of a methyltransferase or a radical SAM enzyme, where the methods and kits comprise, respectively, deaminase TM0936 for a MTase coupled assay and deaminase PA3170 for a radical SAM coupled assay.

Compositions comprise statistically random heteropolymers complexed with active proteins, and are formulated and used in stimuli-responsive materials and nanoreactors composed of proteins and synthetic materials.

Compositions comprise statistically random heteropolymers complexed with active proteins, and are formulated and used in stimuli-responsive materials and nanoreactors composed of proteins and synthetic materials.

Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided. Also provided are compositions and formulations and uses thereof.

The instant disclosure provides methods of detecting N-glycopeptides in a sample by contacting the sample with one or more exoglycosidases and detecting the N-glycopeptides by mass spectrometry. Also provided are methods of detecting the presence or progression of a liver disease and treating said liver disease.

This disclosure relates to biosensors, and in particular, biosensors based on nucleic acid cleaving enzymes such as ribonucleotide-cleaving DNAzymes for the detection of analytes, and methods of use.

Methods are provided for the prognosis, diagnosis and treatment of various pathological states, including cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. The methods provided herein are based on the discovery that various proteins with a high level of sialylation are shown herein to be associated with disease states, such as, cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. Such methods provide a lysosomal exocytosis activity profile comprising one or more values representing lysosomal exocytosis activity. Also provided herein, is the discovery that low lysosomal sialidase activity is associated with various pathological states. Thus, the methods also provide a lysosomal sialidase activity profile, comprising one or more values representing lysosomal sialidase activity. A lysosomal sialidase activity profile is one example of a lysosomal exocytosis activity profile.